Resveratrol and liver: A systematic review

Abstract

Background:Recent studies demonstrated that resveratrol has many therapeutic effects on liver disorders. Resveratrol significantly increased survival after liver transplantation, decreased fat deposition, necrosis, and apoptosis which induced by ischemia in Wistar rats. It provided liver protection against chemical, cholestatic, and alcohol injury. Resveratrol can improve glucose metabolism and lipid profile and decrease liver fibrosis and steatosis. Furthermore, it was able to alter hepatic cell fatty acid composition. According to extension of liver disease around the world and necessity of finding new threat, this review critically examines the current preclinical in vitro and in vivo studies on the preventive and therapeutic effects of resveratrol in liver disorders.Materials and Methods:A search in PubMed, Google Scholar, and Scopus was undertaken to identify relevant literature using search terms, including “liver,” “hepatic,” and “Resveratrol.” Both in vivo and in vitro studies were included. No time limiting considered for this search.Results:A total of 76 articles were eligible for this review. In these articles, resveratrol shows antioxidative properties in different models of hepatitis resulting in reducing of hepatic fibrosis.Conclusion:Resveratrol could reduce hepatic steatosis through modulating the insulin resistance and lipid profile in animals. These high quality preclinical studies propose the potential therapeutic implication of resveratrol in liver disorders especially those with hepatic steatosis. Resveratrol can play a pivotal role in prevention and treatment of liver disorders by reducing hepatic fibrosis.

Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity

“…In our investigations with the PXR wild-type and knockout mice, SIRT1 activation via resveratrol, yielded slightly increased steatosis (~25–30%) when compared with basal levels in wild-type or drug-exposed knockout hepatocytes. Indeed, this contradicts what have been published using rodent models of obesity/diabetes/fat feeding [107]; however, our mice are essentially “normal” and not subject to high-risk features for metabolic syndrome or diabetes. Furthermore, some rodent and clinical studies have provided contradictory findings with respect to SIRT1 activation (resveratrol) in humans [108–111].…”

Effects of dietary resveratrol supplementation during gestation and lactation of sows on milk composition of sows and fat metabolism of sucking piglets

“…In addition, previous studies have reported that resveratrol supplementation reduced liver fat accumulation and increased rates of fatty acid oxidation and promoted the release of energy (Forouzan, Azita, & Payman, 2015). The increase in energy promotes the synthesis of milk fat in the mammary gland (Wang et al, 2016).…”

Natural compounds in the chemoprevention of alcoholic liver disease

“…Resveratrol (3,4′,5-trihydroxy-trans-stilbene), naturally expressed in numerous plants including grapes, berries, and peanuts, is produced in response to environmental stress, microbial injury, or fungal infection (Faghihzadeh, Hekmatdoost, & Adibi, 2015;Luther et al, 2011).…”

“…Previous studies suggested that resveratrol has preventive or therapeutic effects towards a variety of diseases, such as malignancies, neurodegenerative diseases, coronary disease, ischemic injury, and viral infections (Baur & Sinclair, 2006;Saiko, Szakmary, Jaeger, & Szekeres, 2008;Shakibaei, Harikumar, & Aggarwal, 2009;Shankar, Singh, & Srivastava, 2007). Recent studies indicate that resveratrol also has therapeutic effects on liver diseases including ALD and NAFLD (Faghihzadeh et al, 2015;Pan et al, 2014). Given the primary localization of resveratrol in the skin of grapes, it is therefore relatively abundant in red wine.…”